<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02984397</url>
  </required_header>
  <id_info>
    <org_study_id>15-207-MUHC</org_study_id>
    <nct_id>NCT02984397</nct_id>
  </id_info>
  <brief_title>Chronic Widespread Pain and White Blood Cell Activation</brief_title>
  <official_title>Proof of Concept Trial to Test the Efficacy of Treatment With Ketotifen on Pain Sensitivity and Association Between Level of Activity and Reactivity of White Blood Cells and Pain Sensitivity in Teenagers With Chronic Widespread Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University Health Centre/Research Institute of the McGill University Health Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Louise And Alan Edwards Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McGill University Health Centre/Research Institute of the McGill University Health Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our goal is to conduct a proof-of-concept trial to test the efficacy of KF treatment in&#xD;
      adolescents with severe CWP not responding to the standard of care (SOC) treatment program in&#xD;
      a multidisciplinary tertiary care chronic pain clinic. The changes associated to the&#xD;
      interventions (KF or placebo) will be quantified using the Patients' Global Impression of&#xD;
      Change (PGIC) scale after 16 weeks of treatment. Secondary, we aim to evaluate the effects of&#xD;
      KF on the pain sensitivity, physical and emotional functioning, and we will also explore the&#xD;
      potential biological underlying mechanisms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We have designed a proof-of-concept (POC) trial composed of three arms. The first two arms&#xD;
      will be a randomized, controlled, double-blind, parallel-group study, designed to assess the&#xD;
      potential efficacy of KF for the treatment of pain and associated symptoms in adolescent with&#xD;
      CWP. The third arm will consists of assessing standard of care (SOC) data from patients who&#xD;
      do not wish to participate in the study, but agree to allow us to use their SOC data to be&#xD;
      compared with that of patients participating in the study. This arm will help to evaluate the&#xD;
      potential beneficial effect of being part of the study (&quot;placebo&quot; effect) receiving a new&#xD;
      treatment for a condition where the SOC have limited success rate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Actual">January 2020</completion_date>
  <primary_completion_date type="Actual">January 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patients' Global Impression of Change (PGIC) scale</measure>
    <time_frame>Baseline versus week 16</time_frame>
    <description>&quot;Since beginning treatment, how would you describe the change (if any) in ACTIVITY LIMITATIONS, SYMPTOMS, EMOTIONS and OVERALL QUALITY OF LIFE related to your painful condition?&quot; (CHOOSE ONE).&#xD;
No change (or condition has got worse)&#xD;
Almost the same, hardly any change at all&#xD;
A little better, but not noticeable change at all&#xD;
Somewhat better, but the change has not made any real difference&#xD;
Moderately better, and a slight but noticeable change&#xD;
Better, and a definite improvement that has made a real and worthwhile difference&#xD;
A great deal better, and a considerable improvement that has made all the difference&#xD;
Patients scoring either 6 or 7 on the PGIC scale are categorized as &quot;improved&quot;. Patients scoring either 6 or 7 on the PGIC scale are categorized as &quot;improved&quot;. We will use this definition as a dichotomous variable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain sensitivity</measure>
    <time_frame>Baseline versus week 16</time_frame>
    <description>we will use a 0 to 10 numerical ranking scale adapted to RedCap to collect pain intensity ratings. In this scale, '0' means 'no pain at all' and '10' means 'the worst intense pain imaginable'. At baseline, weeks 4, 8, 12 and 16 clinical visits, patients will be asked by the research team to rate their lowest, average, and highest pain intensity for the previous day.&#xD;
Intensity of the lowest, average, and highest pain at 'week 16' will be on of the secondary end points of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with pain sensitivity reduced by half</measure>
    <time_frame>Baseline versus week 16</time_frame>
    <description>We are also interested in the proportion of patients that show a 50% reduction in their pain intensity after 16 weeks of treatment with KF. Thus, we will assess this proportion also for the lowest, average, and highest pain intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily profile of pain index</measure>
    <time_frame>Across baseline and weeks 4, 8, 12 and 16 will be evaluated</time_frame>
    <description>As patients rate their lowest, average, and highest pain intensity daily on RedCap, they will be prompted to indicate also for how many hours each of these pains lasted. The product of pain intensity by pain duration (in hours) will generate the pain index (Example: pain intensity of 9 with a duration of 6 hours = pain index 54)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pressure pain sensitivity</measure>
    <time_frame>Across baseline and weeks 4, 8, 12 and 16 will be evaluated</time_frame>
    <description>Pressure pain thresholds (PPT) will be determined using a digital pressure algometer with a flat round transducer, applied bilaterally at the trapezius muscle and lateral epicondyle. Pressure will be increased at a steady rate of approximately 1 kg/s until the subject indicates that the pressure sensation is perceived as painful sensation (threshold), and the pressure in kg recorded. The first trial at each test site will be considered a practice trial, and will be excluded from data analysis. In subsequent trials, the pressure level at the time the subject indicates to first perceive the pressure sensation to become a painful sensation will be recorded as the threshold estimate. If no response is given at the point the algometer reaches maximum pressure, the maximum value will be used as the threshold value. This procedure will be repeated three times at each test site, and the mean value will be recorded as the subjects threshold.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Disability Inventory</measure>
    <time_frame>Compare values at baseline, with those of weeks 4, 8, 12 and 16.</time_frame>
    <description>The scale can be completed in person, by mail, or by phone. Scoring: item scores range from 0-4. The total FDI score is a sum of all of the items and can be easily hand scored. Scores range from 0-60, with higher scores indicating greater functional disability. (no/minimal disability 0 -12, moderate disability 13-29, and severe disability &gt;30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Revised Child Anxiety and Depression Scale (RCADS)</measure>
    <time_frame>Compare values at baseline, with those of weeks 4, 8, 12 and 16.</time_frame>
    <description>): is a 47-item scale intended to assess children's report of symptoms corresponding to selected DSM-IV anxiety disorders and depression. The RCADS is a 47-item scale with subscales including: separation anxiety disorder (SAD), social phobia (SP), generalized anxiety disorder (GAD), panic disorder (PD), obsessive compulsive disorder (OCD), and major depressive disorder (MDD). It also yields a Total Anxiety Scale (sum of the 5 anxiety subscales) and a Total Internalizing Scale (sum of all 6 subscales). Recall period for item: one week. Scoring programs are available at www.childfirst.ucla.edu/resources for scoring the RCADS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep</measure>
    <time_frame>Compare values at baseline, with those of weeks 4, 8, 12 and 16.</time_frame>
    <description>Pittsburgh Sleep Quality Index (PSQI): 19 items scale assessing sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medications, and daytime dysfunction. Recall period for item: one month Scoring: Point values of each item in of the seven subscales are summed and then combined as indicated to generate a subscale score. These totals are summed to create the global PSQI score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Role Functioning</measure>
    <time_frame>Compare values at baseline, with those of weeks 4, 8, 12 and 16.</time_frame>
    <description>Patients will be asked at each evaluation to quantify the number of days lost because of pain and/or associated symptoms in the previous four weeks. Days of school missed because of medical appointments will not be quantified for the role functioning analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic medication reduction</measure>
    <time_frame>Compare baseline with weeks 4, 8, 12 and 16.</time_frame>
    <description>Patients will be allowed to reduce the doses or, eventually, to stop the use analgesic medication under medical supervision if there is a significant reduction in pain intensity (50% reduction in pain intensity rating) or in the associated symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Compare weeks 4, 8, 12 and 16.</time_frame>
    <description>We will use an electronic list of adverse reactions to check for treatment-emergent adverse events. This list was created by us to run on RedCap, based on the list of adverse reactions reported by patients participating in a double-blind, placebo controlled Canadian Multicentre Trial (196 asthmatic children aged 5- 17 years) (Rackham, A. et al. A Canadian multicenter study with Zaditen (ketotifen) in the treatment of bronchial asthma in children aged 5 to 17 years. The Journal of allergy and clinical immunology 84, 286-296 (1989).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RNA expression</measure>
    <time_frame>Baseline versus week 16</time_frame>
    <description>RNA expression patterns will be compared before and after treatment,</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Widespread Chronic Pain</condition>
  <arm_group>
    <arm_group_label>KF group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In each study visit, patients will receive enough pills for the next month. At the first visit, patients receiving ketotifen (KF) will receive four vials sequentially numbered (1 to 4) containing enough pills for one week each, and will be instructed by the clinician and by the pharmacist to use vial 1 for the first week (0.5 mg of KF BDI), vial 2 for the second week (1mg of KF BDI), vial 3 for the third week (2 mg of KF BDI), and vial 4 for the fourth week (3mg of KF BDI). As for weeks 4, 8 and 12 visits, patients treated with KF will receive four equal vials containing enough pills for one week each (3 mg of KF BDI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients participating in the placebo group will also receive sequentially numbered vials at the first visit. Similarly, patients taking placebo will also receive four equal vials of pills on the next visits.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care - patients who refuse to participate in the study but allow us to compare their clinical data to that of participants of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketotifen Fumarate</intervention_name>
    <description>Ketotifen is a second-generation noncompetitive H1-antihistamine and mast cell stabilizer. It is most commonly sold as a salt with fumaric acid, ketotifen fumarate, and is available in two forms. In its ophthalmic form, it is used to treat allergic conjunctivitis, or the itchy red eyes caused by allergies. In its oral form, it is used to prevent asthma attacks.</description>
    <arm_group_label>KF group</arm_group_label>
    <other_name>Zaditen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <arm_group_label>SOC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female and male adolescents aged between 14 to 18 years old;&#xD;
&#xD;
          -  For female adolescents of child bearing potential: negative serum pregnancy test at&#xD;
             base line screening;&#xD;
&#xD;
          -  For female adolescents of child bearing potential: being willing and able to use&#xD;
             contraceptive methods for the duration of the study and for 30 days after receiving&#xD;
             the last dose of the study drug;&#xD;
&#xD;
          -  Diffuse body pain that has been present for at least 3 months, and who also have&#xD;
             symptoms of fatigue, sleep disturbance, cognitive changes and mood disorder;&#xD;
&#xD;
          -  Accompanied by at least one somatic symptoms to variable degree including irritable&#xD;
             bowel syndrome, headaches, menstrual pain, lower urinary tract symptoms, myofascial&#xD;
             pain, and temporomandibular pain;&#xD;
&#xD;
          -  Symptoms cannot be explained by some other illness;&#xD;
&#xD;
          -  Physical examination which should be within normal limits except for tenderness on&#xD;
             pressure of soft tissues (i.e. tactile hyperalgesia which is increased pain following&#xD;
             a painful stimulus)&#xD;
&#xD;
          -  Overall body pain average score ≥ 4&#xD;
&#xD;
          -  Moderate to severe physical impairment Functional Disability Inventory &gt; 12 points.&#xD;
&#xD;
          -  Stable doses of his/her current medication for at least four weeks&#xD;
&#xD;
          -  Not having significant changes in their health conditions (PIGS less than 6 points)&#xD;
             after 8 weeks of treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Be part of other trials;&#xD;
&#xD;
          -  Have a specific diagnosis that can explain the symptoms; including rheumatoid&#xD;
             arthritis, systemic lupus erythematosus, scleroderma and/or other connective tissue&#xD;
             diseases&#xD;
&#xD;
          -  Refuse to donate blood sample;&#xD;
&#xD;
          -  Not be able to fill electronic records;&#xD;
&#xD;
          -  Cognitive impairment interfering with the clinical evaluations;&#xD;
&#xD;
          -  Known intolerance or allergies to KF;&#xD;
&#xD;
          -  Been under treatment with other mast cell stabilizer agent;&#xD;
&#xD;
          -  Seizures history or actual treatment;&#xD;
&#xD;
          -  Coagulopathies or chronic thrombocytopenia;&#xD;
&#xD;
          -  Atopic dermatitis (eczema) or chronic urticaria (hives)&#xD;
&#xD;
          -  Schizophrenia or bipolar disorder&#xD;
&#xD;
          -  Elective surgery within the study timeline&#xD;
&#xD;
          -  Abnormal labs results (i.e., elevated SGPT and low platelet count, low Hb or Ht) in&#xD;
             the last 6 months or in the base line evaluation&#xD;
&#xD;
          -  Patients who are pregnant or are breast-feeding;&#xD;
&#xD;
          -  Patients who are on oral antidiabetic agents;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>McGill University Health Centre (MUHC) - Montreal Children's Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 2, 2016</study_first_submitted>
  <study_first_submitted_qc>December 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2016</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</investigator_affiliation>
    <investigator_full_name>Pablo Ingelmo</investigator_full_name>
    <investigator_title>Associate Professor, Department of Anesthesia; Director, Chronic Pain Service (Pediatric), Montreal Children's Hospital</investigator_title>
  </responsible_party>
  <keyword>pain</keyword>
  <keyword>ketotifen</keyword>
  <keyword>pediatric</keyword>
  <keyword>mast cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketotifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02984397
org study id: 15-207-MUHC
nct id: NCT02984397
lead sponsor: 
collaborator: 
has dmc: No
Our goal is to conduct a proof-of-concept trial to test the efficacy of KF treatment in
      adolescents with severe CWP not responding to the standard of care (SOC) treatment program in
      a multidisciplinary tertiary care chronic pain clinic. The changes associated to the
      interventions (KF or placebo) will be quantified using the Patients' Global Impression of
      Change (PGIC) scale after 16 weeks of treatment. Secondary, we aim to evaluate the effects of
      KF on the pain sensitivity, physical and emotional functioning, and we will also explore the
      potential biological underlying mechanisms.
We have designed a proof-of-concept (POC) trial composed of three arms. The first two arms
      will be a randomized, controlled, double-blind, parallel-group study, designed to assess the
      potential efficacy of KF for the treatment of pain and associated symptoms in adolescent with
      CWP. The third arm will consists of assessing standard of care (SOC) data from patients who
      do not wish to participate in the study, but agree to allow us to use their SOC data to be
      compared with that of patients participating in the study. This arm will help to evaluate the
      potential beneficial effect of being part of the study ("placebo" effect) receiving a new
      treatment for a condition where the SOC have limited success rate.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: Triple (Participant, Care Provider, Investigator)
measure: Patients' Global Impression of Change (PGIC) scale
time frame: Baseline versus week 16
description: "Since beginning treatment, how would you describe the change (if any) in ACTIVITY LIMITATIONS, SYMPTOMS, EMOTIONS and OVERALL QUALITY OF LIFE related to your painful condition?" (CHOOSE ONE).
No change (or condition has got worse)
Almost the same, hardly any change at all
A little better, but not noticeable change at all
Somewhat better, but the change has not made any real difference
Moderately better, and a slight but noticeable change
Better, and a definite improvement that has made a real and worthwhile difference
A great deal better, and a considerable improvement that has made all the difference
Patients scoring either 6 or 7 on the PGIC scale are categorized as "improved". Patients scoring either 6 or 7 on the PGIC scale are categorized as "improved". We will use this definition as a dichotomous variable.
measure: Pain sensitivity
time frame: Baseline versus week 16
description: we will use a 0 to 10 numerical ranking scale adapted to RedCap to collect pain intensity ratings. In this scale, '0' means 'no pain at all' and '10' means 'the worst intense pain imaginable'. At baseline, weeks 4, 8, 12 and 16 clinical visits, patients will be asked by the research team to rate their lowest, average, and highest pain intensity for the previous day.
Intensity of the lowest, average, and highest pain at 'week 16' will be on of the secondary end points of the study.
measure: Proportion of patients with pain sensitivity reduced by half
time frame: Baseline versus week 16
description: We are also interested in the proportion of patients that show a 50% reduction in their pain intensity after 16 weeks of treatment with KF. Thus, we will assess this proportion also for the lowest, average, and highest pain intensity.
measure: Daily profile of pain index
time frame: Across baseline and weeks 4, 8, 12 and 16 will be evaluated
description: As patients rate their lowest, average, and highest pain intensity daily on RedCap, they will be prompted to indicate also for how many hours each of these pains lasted. The product of pain intensity by pain duration (in hours) will generate the pain index (Example: pain intensity of 9 with a duration of 6 hours = pain index 54)
measure: Pressure pain sensitivity
time frame: Across baseline and weeks 4, 8, 12 and 16 will be evaluated
description: Pressure pain thresholds (PPT) will be determined using a digital pressure algometer with a flat round transducer, applied bilaterally at the trapezius muscle and lateral epicondyle. Pressure will be increased at a steady rate of approximately 1 kg/s until the subject indicates that the pressure sensation is perceived as painful sensation (threshold), and the pressure in kg recorded. The first trial at each test site will be considered a practice trial, and will be excluded from data analysis. In subsequent trials, the pressure level at the time the subject indicates to first perceive the pressure sensation to become a painful sensation will be recorded as the threshold estimate. If no response is given at the point the algometer reaches maximum pressure, the maximum value will be used as the threshold value. This procedure will be repeated three times at each test site, and the mean value will be recorded as the subjects threshold.
measure: Functional Disability Inventory
time frame: Compare values at baseline, with those of weeks 4, 8, 12 and 16.
description: The scale can be completed in person, by mail, or by phone. Scoring: item scores range from 0-4. The total FDI score is a sum of all of the items and can be easily hand scored. Scores range from 0-60, with higher scores indicating greater functional disability. (no/minimal disability 0 -12, moderate disability 13-29, and severe disability >30)
measure: Revised Child Anxiety and Depression Scale (RCADS)
time frame: Compare values at baseline, with those of weeks 4, 8, 12 and 16.
description: ): is a 47-item scale intended to assess children's report of symptoms corresponding to selected DSM-IV anxiety disorders and depression. The RCADS is a 47-item scale with subscales including: separation anxiety disorder (SAD), social phobia (SP), generalized anxiety disorder (GAD), panic disorder (PD), obsessive compulsive disorder (OCD), and major depressive disorder (MDD). It also yields a Total Anxiety Scale (sum of the 5 anxiety subscales) and a Total Internalizing Scale (sum of all 6 subscales). Recall period for item: one week. Scoring programs are available at www.childfirst.ucla.edu/resources for scoring the RCADS.
measure: Sleep
time frame: Compare values at baseline, with those of weeks 4, 8, 12 and 16.
description: Pittsburgh Sleep Quality Index (PSQI): 19 items scale assessing sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medications, and daytime dysfunction. Recall period for item: one month Scoring: Point values of each item in of the seven subscales are summed and then combined as indicated to generate a subscale score. These totals are summed to create the global PSQI score.
measure: Role Functioning
time frame: Compare values at baseline, with those of weeks 4, 8, 12 and 16.
description: Patients will be asked at each evaluation to quantify the number of days lost because of pain and/or associated symptoms in the previous four weeks. Days of school missed because of medical appointments will not be quantified for the role functioning analysis.
measure: Analgesic medication reduction
time frame: Compare baseline with weeks 4, 8, 12 and 16.
description: Patients will be allowed to reduce the doses or, eventually, to stop the use analgesic medication under medical supervision if there is a significant reduction in pain intensity (50% reduction in pain intensity rating) or in the associated symptoms
measure: Adverse events
time frame: Compare weeks 4, 8, 12 and 16.
description: We will use an electronic list of adverse reactions to check for treatment-emergent adverse events. This list was created by us to run on RedCap, based on the list of adverse reactions reported by patients participating in a double-blind, placebo controlled Canadian Multicentre Trial (196 asthmatic children aged 5- 17 years) (Rackham, A. et al. A Canadian multicenter study with Zaditen (ketotifen) in the treatment of bronchial asthma in children aged 5 to 17 years. The Journal of allergy and clinical immunology 84, 286-296 (1989).
measure: RNA expression
time frame: Baseline versus week 16
description: RNA expression patterns will be compared before and after treatment,
arm group label: KF group
arm group type: Experimental
description: In each study visit, patients will receive enough pills for the next month. At the first visit, patients receiving ketotifen (KF) will receive four vials sequentially numbered (1 to 4) containing enough pills for one week each, and will be instructed by the clinician and by the pharmacist to use vial 1 for the first week (0.5 mg of KF BDI), vial 2 for the second week (1mg of KF BDI), vial 3 for the third week (2 mg of KF BDI), and vial 4 for the fourth week (3mg of KF BDI). As for weeks 4, 8 and 12 visits, patients treated with KF will receive four equal vials containing enough pills for one week each (3 mg of KF BDI)
arm group label: Placebo group
arm group type: Placebo Comparator
description: Patients participating in the placebo group will also receive sequentially numbered vials at the first visit. Similarly, patients taking placebo will also receive four equal vials of pills on the next visits.
arm group label: SOC
arm group type: Active Comparator
description: Standard of care - patients who refuse to participate in the study but allow us to compare their clinical data to that of participants of the study
intervention type: Drug
intervention name: Ketotifen Fumarate
description: Ketotifen is a second-generation noncompetitive H1-antihistamine and mast cell stabilizer. It is most commonly sold as a salt with fumaric acid, ketotifen fumarate, and is available in two forms. In its ophthalmic form, it is used to treat allergic conjunctivitis, or the itchy red eyes caused by allergies. In its oral form, it is used to prevent asthma attacks.
arm group label: KF group
other name: Zaditen
intervention type: Drug
intervention name: Placebo
arm group label: Placebo group
intervention type: Other
intervention name: Standard of Care
arm group label: SOC
criteria: 
gender: All
minimum age: 14 Years
maximum age: 18 Years
healthy volunteers: No
facility: 
country: Canada
responsible party type: Principal Investigator
investigator affiliation: McGill University Health Centre/Research Institute of the McGill University Health Centre
investigator full name: Pablo Ingelmo
investigator title: Associate Professor, Department of Anesthesia; Director, Chronic Pain Service (Pediatric), Montreal Children's Hospital
mesh term: Chronic Pain
mesh term: Ketotifen